Journal article
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Abstract
BACKGROUND: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous …
Authors
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L
Journal
The Lancet, Vol. 394, No. 10193, pp. 121–130
Publisher
Elsevier
Publication Date
July 2019
DOI
10.1016/s0140-6736(19)31149-3
ISSN
0140-6736